MX2023001111A - Metodo para el uso de una molecula pd-1 x ctla-4 biespecifica. - Google Patents

Metodo para el uso de una molecula pd-1 x ctla-4 biespecifica.

Info

Publication number
MX2023001111A
MX2023001111A MX2023001111A MX2023001111A MX2023001111A MX 2023001111 A MX2023001111 A MX 2023001111A MX 2023001111 A MX2023001111 A MX 2023001111A MX 2023001111 A MX2023001111 A MX 2023001111A MX 2023001111 A MX2023001111 A MX 2023001111A
Authority
MX
Mexico
Prior art keywords
ctla
bispecific molecule
methods
cancer
molecules
Prior art date
Application number
MX2023001111A
Other languages
English (en)
Spanish (es)
Inventor
Ezio Bonvini
Jon Marc Wigginton
Bradley James Sumrow
Alexey Yevgenyevich Berezhnoy
Sharad Sharma
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MX2023001111A publication Critical patent/MX2023001111A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
MX2023001111A 2020-07-27 2021-07-23 Metodo para el uso de una molecula pd-1 x ctla-4 biespecifica. MX2023001111A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063057054P 2020-07-27 2020-07-27
US202163177036P 2021-04-20 2021-04-20
US202163219066P 2021-07-07 2021-07-07
PCT/US2021/042901 WO2022026306A1 (en) 2020-07-27 2021-07-23 Methods for the use of a pd-1 x ctla-4 bispecific molecule

Publications (1)

Publication Number Publication Date
MX2023001111A true MX2023001111A (es) 2023-03-07

Family

ID=80036053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001111A MX2023001111A (es) 2020-07-27 2021-07-23 Metodo para el uso de una molecula pd-1 x ctla-4 biespecifica.

Country Status (13)

Country Link
US (1) US20230312756A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188961A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023536086A (cg-RX-API-DMAC7.html)
KR (1) KR20230042038A (cg-RX-API-DMAC7.html)
CN (1) CN116134053A (cg-RX-API-DMAC7.html)
AU (1) AU2021316192A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001487A2 (cg-RX-API-DMAC7.html)
CA (1) CA3189926A1 (cg-RX-API-DMAC7.html)
IL (1) IL300166A (cg-RX-API-DMAC7.html)
MX (1) MX2023001111A (cg-RX-API-DMAC7.html)
TW (1) TW202220691A (cg-RX-API-DMAC7.html)
WO (1) WO2022026306A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202300822B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物
WO2026021409A1 (zh) * 2024-07-22 2026-01-29 宜明昂科生物医药技术(上海)股份有限公司 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法
WO2026067794A1 (en) * 2024-09-30 2026-04-02 Shen Shi Pharmaceuticals (Shanghai) Co., Ltd. Trispecific antibodies and uses thereof
WO2026117666A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Bispecific antibodies for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
CN108367069B (zh) * 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
US20190241658A1 (en) * 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
CA3026151A1 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2019179421A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
US20210079094A1 (en) * 2019-03-29 2021-03-18 Xencor, Inc. Dosing of a bispecific antibody that binds pd1 and ctla4

Also Published As

Publication number Publication date
TW202220691A (zh) 2022-06-01
EP4188961A4 (en) 2024-08-07
ZA202300822B (en) 2023-08-30
KR20230042038A (ko) 2023-03-27
AU2021316192A1 (en) 2023-02-23
US20230312756A1 (en) 2023-10-05
EP4188961A1 (en) 2023-06-07
CA3189926A1 (en) 2022-02-03
BR112023001487A2 (pt) 2023-02-14
JP2023536086A (ja) 2023-08-23
CN116134053A (zh) 2023-05-16
IL300166A (en) 2023-03-01
WO2022026306A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
ZA202300822B (en) Methods for the use of a pd-1 x ctla-4 bispecific molecule
MX2022007790A (es) Terapia para el tratamiento del cancer.
EP4501352A3 (en) Compositions and methods for car t cell therapy
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2024013526A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
SA522433129B1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
EA202190181A1 (ru) Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1
BR112022002831A2 (pt) Formulações anti-c5 de alta concentração
EA201992757A1 (ru) Биспецифические антитела-ингибиторы контрольной точки
MX2019002474A (es) Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
MX2022015748A (es) Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer.
ZA201907225B (en) Treatment of her2 positive cancers
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
WO2023097194A3 (en) Bicyclic therapeutic compounds and methods of use in the treatment of cancer
MX2020002301A (es) Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico.
PH12022553153A1 (en) Binding molecules for the treatment of cancer
ZA202211455B (en) Methods for the use of a b7-h3 antibody-drug conjugate alone or in combination
EA201892797A1 (ru) Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака
MX2022015475A (es) Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma.
WO2019136157A3 (en) Reducing beta-catenin and ido expression to potentiate immunotherapy
MX2024015058A (es) Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer
MX2024012392A (es) Terapia combinada para el tratamiento del cancer
MX2020002266A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.
MX2024012368A (es) Terapia combinada para el tratamiento del cancer